Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 23, 2009

JCOM to Use GTC Biotherapeutics’ Cell Lines for Insulin Production in Asia

  • GTC Biotherapeutics entered into a license agreement with JCOM in the Republic of Korea to provide a license for the transgenic development of recombinant human insulin products in Asia. JCOM will pay a license fee and compensate GTC for successful development of the transgenic production system. JCOM will also pay GTC a royalty on any commercial sales of the products.

    Under the agreement, GTC will establish the appropriate cell lines and demonstrate production over the next 12 months. JCOM has the option for exclusive marketing rights in Asia.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »